无可比拟的注册研究表明,在42.5%的前列腺癌病例中,基于SPECT的PSMA成像改变了治疗方法。 NOBLE Registry study shows SPECT-based PSMA imaging altered treatment in 42.5% of prostate cancer cases.

Telix制药公司和Oncidium基金会宣布在EJNMMI报告中公布《诺贝尔登记册》的结果。 Telix Pharmaceuticals and the Oncidium Foundation announced the publication of the NOBLE Registry results in EJNMMI Reports. 这项研究涉及6个国家的40名病人,发现基于SPECT的PSMA成像改变了42.5%的病例的管理,没有发生不良事件。 The study, involving 40 patients across six countries, found that SPECT-based PSMA imaging changed management in 42.5% of cases without adverse events. 结果表明,基于技术的成像可增进全球获得前列腺癌诊断的机会,从而导致进一步的临床研究和扩大使用的潜在伙伴关系。 The results suggest technetium-based imaging could enhance global access to prostate cancer diagnostics, leading to further clinical studies and potential partnerships for expanded use.